Relative importance of transport and alkylation for pancreatic beta-cell toxicity of streptozotocin

Diabetologia

Volumn 43, Issue 12, 2000, Pages 1528-1533

  Elsner, M ^a   Guldbakke, B ^a   Tiedge, M ^a   Munday, R ^a   Lenzen, S ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Diabetes; Glucose transporter GLUT2; RINm5F cells; Streptozotocin; Streptozotocin derivatives

Indexed keywords

ALKYLATING AGENT; COMPLEMENTARY DNA; ETHYLNITROSOUREA; GLUCOSE TRANSPORTER; GLUCOSE TRANSPORTER 2; MESYLIC ACID ETHYL ESTER; MESYLIC ACID METHYL ESTER; METHYLNITROSOUREA; STREPTOZOCIN; UNCLASSIFIED DRUG; VIRUS VECTOR;

ALKYLATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL VIABILITY; CONTROLLED STUDY; CYTOMEGALOVIRUS; CYTOPATHOGENIC EFFECT; DIABETOGENESIS; GENETIC TRANSFECTION; NONHUMAN; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; STREPTOZOCIN DIABETES;

3-O-METHYLGLUCOSE; ALKYLATING AGENTS; ALKYLATION; ANIMALS; BIOLOGICAL TRANSPORT; BIOTRANSFORMATION; CELL LINE; CELL SURVIVAL; ETHYL METHANESULFONATE; ETHYLNITROSOUREA; GLUCOSE TRANSPORTER TYPE 2; ISLETS OF LANGERHANS; KINETICS; METHYL METHANESULFONATE; METHYLNITROSOUREA; MONOSACCHARIDE TRANSPORT PROTEINS; RATS; RECOMBINANT PROTEINS; STREPTOZOCIN; TRANSFECTION;

EID: 0034434893     PISSN: 0012186X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001250051564     Document Type: Article

References (43)

1. Drugs producing diabetes through damage of the insulin secreting cells
2. Streptozotocin diabetes. Correlation with extent of depression of pancreatic islet nicotinamide adenine dinucleotide
3. Streptozocin: A review of its pharmacology, efficacy, and toxicity
4. Modification of streptozotozin-induced diabetes by protective agents
5. GLUT2 in pancreatic islets: Crucial target molecule in diabetes induced with multiple low doses of streptozotocin in mice
6. Alkylation of DNA in rat tissues following administration of streptozotocin
7. Clinical antitumor activity and toxicity of streptozotocin (NSC-85 998)
8. Cytotoxic effects of streptozotocin and N-nitrosomethylurea on the pancreatic B cells with special regard to the role of nicotin-amide- adenine dinucleotide
9. Alloxan derivatives as a tool for the elucidation of the mechanism of the diabetogenic action of alloxan
10. Effects of streptozotocin on a clonal isolate of rat insulinoma cells
11. Effects of cytotoxic drugs and inhibitors of insulin secretion on a serially transplantable rat insulinoma and cultured rat insulinoma cells
12. STZ transport and cytotoxicity. Specific enhancement in GLUT2- expressing cells
13. Mechanisms of nitrosourea-induced beta-cell damage. Alterations in DNA
14. Mechanisms of nitrosourea-induced beta-cell damage. Activation of poly (ADP-ribose) synthetase and cellular distribution
15. Protection by superoxide dismutase, catalase, and poly(ADP-ribose) synthetase inhibitors against alloxan- and streptozotocin-induced islet DNA strand breaks and against the inhibition of proinsulin synthesis
16. Site-specific DNA methylation and apoptosis: Induction by diabetogenic streptozotocin
17. Isolation and partial characterization of human cell mutants differing in sensitivity to killing and mutation by methylnitrosourea and N- methyl-N'-nitro-N-nitrosoguanidine
18. Properties of N-methyl-N-nitrosourea-resistant, Mex- derivatives of an SV40-immortalized human fibroblast cell line
19. Self-destruction and tolerance in resistance of mammalian cells to alkylation damage
20. Streptozotocin and alloxan induce DNA strand breaks and poly(ADP-ribose) synthetase in pancreatic islets
21. DNA strand breaks in pancreatic islets by in vivo administration of alloxan or streptozotocin
22. Poly(ADP-bose) polymerase-deficient mice are protected from streptozotocin-induced diabetes
23. Mice lacking the poly(ADP-ribose) polymerase gene are resistant to pancreatic beta-cell destruction and diabetes development induced by streptozocin
24. Poly(ADP-ribose) polymerase gene disruption conferred mice resistant to streptozotocin-induced diabetes
25. Poly (ADP-ribose) polymerase, nitric oxide and cell death
26. Biochemical evidence for nitric oxide formation from streptozotocin in isolated pancreatic islets
27. Nitric oxide generation from streptozotocin
28. Constitutive nitric oxide synthase from cerebellum is reversibly inhibited by nitric oxide formed from L-arginine
29. N-monomethyl-arginine and nicotinamide prevent streptozotocin-induced double strand DNA break formation in pancreatic rat islets
30. Apoptotic cell death triggered by nitric oxide in pancreatic beta-cells
31. Nitric oxide generation during cellular metabolization of the diabetogenic N-methyl-N-nitroso-urea streptozotozin contributes to islet cell DNA damage
32. Protection against the co-operative toxicity of nitric oxide and oxygen free radicals by overexpression of antioxidant enzymes in bioengineered insulin-producing RINm5F cells
33. 6-alkylating ability
34. Metabolic regulation, activity state, and intracellular binding of glucokinase in insulin-secreting cells
35. Relation between antioxidant enzyme gene expression and antioxidative defense status of insulin-producing cells
36. MTT-assay and neutral red release (NRR)-assay: Relative role in the prediction of the irritancy potential of surfactants
37. Insulin secretion by isolated perfused rat and mouse pancreas
38. Insulin secretion, insulin content and glucose phosphorylation in RINm5F insulinoma cells after transfection with human GLUT2 glucose- transporter cDNA
39. DNA fluorometric assay in 96-well tissue culture plates using Hoechst 33 258 after cell lysis by freezing in destilled water
40. Cloning and functional expression in bacteria of a novel glucose transporter present in liver, intestine, kidney, and beta-pancreatic islet cells
41. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenolchloroform extraction
42. Intestinal epithelial cell surface membrane glycoprotein synthesis. II. Glycosyltransferases and endogenous acceptors of the undifferentiated cell surface membrane
43. Engineering of a glucose-responsive surrogate cell for insulin replacement therapy of experimental insulin-dependent diabetes